ClinicalTrials.gg
CompletedNCT06478979Updated Aug 24, 2026

The Pilot Study of Medical Device-Neuclare for Patients With Idiopathic Normal Pressure Hydrocephalus (iNPH)

An interventional study of Neuclare in Idiopathic Normal Pressure Hydrocephalus (iNPH), sponsored by Deepsonbio. Completed at 1 site in South Korea. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Deepsonbio · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
60 Years to 90 Years
Sex
All
01

Study summary

This clinical trial aims to explore the effectiveness and safety of gait improvemen of Neuclare, a science medical device, for patients with Idiopathic Normal Pressure Hydrocephalus (iNPH) Through methods such as Timed Up \& Go Test (TUG), 10m gait , iNPH grading scale), etc, gait improvement before and after using Neuclare will be evaluated.

02

Conditions studied

  • Idiopathic Normal Pressure Hydrocephalus (iNPH)
03

In context

Hydrocephalus, Normal Pressure

78 studies on the registry are indexed under Hydrocephalus, Normal Pressure; 20 are open to participants now.

This study's enrollment of 20 is below the median of 49 across 40 interventional studies indexed under Hydrocephalus, Normal Pressure.

Browse Hydrocephalus, Normal Pressure studies →

Lead sponsor

Deepsonbio is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 60 to 90, regardless of gender
  • Individuals exhibiting gait disturbances along with at least one of the following symptoms: cognitive impairment or urinary incontinence
  • Evans' index > 0.3)
  • When the symptoms in 2) and 3) cannot be fully explained by other neurological or non-neurological diseases
  • Diagnosis of INPH based on the Investigator's clinical judgement based on criteria as described in the INPH Guidelines

Exclusion criteria

Exclusion Criteria:

  • Patient with pathological lesions in the brain identified by MRI
  • A person who is confirmed to have organic brain lesions (e.g., cerebral edema, cerebral hemorrhage, cerebral infarction, cerebrovascular malformation, brain tumor, etc.) on a brain MRI.
  • Patients with metabolic disorders such as thyroid dysfunction, hyperglycemia, hypoglycemia, liver or kidney dysfunction, and long-term use of drugs that will cause cognitive decline (e.g., anticholinergic drugs)
  • History of psychiatric disorder other than the inclusion criteria.
  • A person with a severe history of cancer/tuberculosis
  • A person who has contact dermatitis or sensitive skin abnormalities
  • Patients with a high fever of 40 degrees Celsius or higher based on eardrum body temperature
  • A person whose bleeding is identified due to a common procedure or surgery that may affect vital signs
  • A person who is unable to perform MRI tests
  • A person with an allergic reaction to MRI contrast agents such as Definity or Gadovist.
  • Other cases where the investigator judged that it is difficult to participate in the study
  • Patient with behavioral and psychological symptoms of dementia (BPSD) that make cooperation in the clinical trial difficult
  • Patients with severe cognitive impairment, defined as an score of 17 or below
  • Patients who have undergone shunt surgery in the past year
  • Patients with a history of uncontrolled thyroid, liver, or kidney dysfunction
  • Patients taking medications that affect gait, cognition, or urinary tract function and who have had a change in medication regimen within the past 3 months.
  • Patients who have undergone a cerebrospinal fluid drainage test within the past 1 month.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment group

    The patient with Idiopathic Normal Pressure Hydrocephalus (iNPH) who will be treated with the medical device-Neuclare

    Device: Neuclare

Interventions

  • DeviceNeuclare

    It is used to stimulate the brain for a certain period of time to assess gait improvement in patients with Idiopathic Normal Pressure Hydrocephalus (iNPH). In this clinical trial, it is used for patients with Idiopathic Normal Pressure Hydrocephalus (iNPH).

06

What researchers measure

Primary outcomes

  1. Change of Time Up & Go Test : From Baseline to Week 1

    Compare with before and after using Neuclare for the treatment of Idiopathic Normal Pressure Hydrocephalus (iNPH) as evaluated by Time Up \& Go Test

    Time frame: Week 1

Secondary outcomes

  1. Change of 10m gait : From Baseline to Week 1

    Compare with before and after using Neuclare for the treatment of Idiopathic Normal Pressure Hydrocephalus (iNPH) as evaluated by 10m gait

    Time frame: Week 1

  2. Change of iNPH grading scale : From Baseline to Week 1

    Compare with before and after using Neuclare for the treatment of Idiopathic Normal Pressure Hydrocephalus (iNPH) as evaluated by iNPH grading scale. The overall score may reach values between 0 and 12, with higher scores indicating more severe impairment

    Time frame: Week 1

  3. Change of Trail Making Test Black & White Score : From Baseline to Week 1

    Compare with before and after using Neuclare for the treatment of Idiopathic Normal Pressure Hydrocephalus (iNPH) as evaluated by Change of Trail Making Test Black \& White Score. The higher scores mean a worse outcome.

    Time frame: Week 1

  4. Change of Modified Rankin Scale(mRS) : From Baseline to Week 1

    Compare with before and after using Neuclare for the treatment of Idiopathic Normal Pressure Hydrocephalus (iNPH) as evaluated by Modified Rankin Scale(mRS). Assessment results range from 0-6 points,a higher score means a worse ending

    Time frame: Week 1

  5. Change of Quality of life-AD Score : From Baseline to Week 1

    Compare with before and after using Neuclare for the treatment of Idiopathic Normal Pressure Hydrocephalus (iNPH) as evaluated by Change of Quality of life-AD Score. QoL-AD was comprised of 13 individual items, each measured on a 4-point Likert scale (ranging from 1 \[poor\] to 4 \[excellent\]). Overall QoL-AD score was the sum of the scores for the 13 individual items and ranged from 13 to 52, with higher scores indicating a higher health related quality of life.

    Time frame: Week 1

  6. Change of MMSE-II Score : From Baseline to Week 5

    Compare with before and after using Neuclare for the treatment of Idiopathic Normal Pressure Hydrocephalus (iNPH) as evaluated by Change of MMSE-II Score. The cognitive function evaluation performed by MMSE test. The Total score range of MMSE is 0-30, and the higher score indicates better cognitive functions.

    Time frame: Week 1

  7. Change in glymphatic activity, structure, functional connectivity measured by MRI: From Baseline to Week 1

    Compare with before and after using Neuclare for the treatment of Idiopathic Normal Pressure Hydrocephalus (iNPH) as evaluated by Change in glymphatic activity, structure, functional connectivity measured by MRI

    Time frame: Week 1

07

Study locations

1 site
  • Hallym University Dongtan Sacred Heart Hospital
    Hwaseong-si, Gyeonggi-do 18450, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Nov 2025, 15 months.

Of 21 interventional studies with no phase under Hydrocephalus, Normal Pressure, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2024
First posted
Jun 27, 2024
StartActual
Jul 22, 2024
Primary completionActual
Nov 21, 2025
CompletionActual
Nov 21, 2025
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06478979
Lead sponsor
Deepsonbio
Responsible party
Sponsor
First posted
Jun 27, 2024
Start date
Jul 22, 2024
Primary completion
Nov 21, 2025
Completion
Nov 21, 2025
Last update
Aug 24, 2026

Study contacts

Jaeho Kim, M.D. Ph.D
principal investigator · Hallym University Dongtan Sacred Heart Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion